Lotte Biologics Hosts Technology Development Forum to Foster Future Innovation Technologies
Fifth Forum Features Keynote Lecture by Jaeuk Jung, Head of R&D at GC Green Cross
Lotte Biologics announced on December 12 that it held the "Future Innovation Technology Development Forum" for all employees at the multipurpose hall of the IBS Tower in Songdo, Incheon.
Since last year, the company has been regularly hosting forums on the latest biopharmaceutical development and production technologies to strengthen technological differentiation and collaboration in the global market. The forum also serves as a platform for interaction between employees at its campuses in Korea and the Syracuse Bio Campus in New York.
This fifth forum featured Jaeuk Jung, Head of R&D at GC Green Cross, as the keynote speaker, and was also attended by Byungchul Lee, CEO of Cana Therapeutics.
Jaeuk Jung, Head of Technology Development Division at GC Green Cross, is presenting at the Technology Development Forum of Lotte Biologics. Lotte Biologics
View original imageDuring the forum, Jaeuk Jung introduced the current landscape of the bio industry and the latest trends in antibody-drug conjugates (ADCs), delivering a presentation titled "Evolving from traditional approaches to innovative breakthroughs."
He provided an overview of GC Green Cross's pipeline and shared updates on the company's recent entry into the ADC field. Jung addressed the limitations of conventional cytotoxic anticancer therapies, which attack not only rapidly dividing cancer cells but also healthy cells, causing side effects. He highlighted the differentiated advantages of ADCs, which combine antibodies and anticancer drugs to selectively deliver medication to cancer cells, thereby minimizing damage to normal cells.
Lotte Biologics’ "SoluFlex Linker" technology is an innovative conjugation platform that enables precise drug delivery and targeted attacks for ADCs, enhancing both efficacy and safety. Based on a proprietary hydrophilic linker, it can be applied to a variety of payloads and maintains high yields even under challenging conditions. This results in superior in vivo efficacy, pharmacokinetics, safety, and productivity compared to conventional ADC therapies, making it a promising platform for next-generation ADC development and commercial production.
The ADC manufacturing facility at Lotte Biologics’ Syracuse Bio Campus in New York provides one-stop CDMO (contract development and manufacturing organization) services, covering everything from clinical development to commercial production to meet client needs.
Jaeuk Jung stated, "We are conducting various research projects with technologically advanced partners, and in particular, we are striving to secure higher-value assets through collaboration with Cana Therapeutics, which possesses core ADC linker technology."
He added, "Not only with early clinical data but also through joint research projects and the development of diverse therapeutic technologies targeting the global market, Lotte Biologics, with its production facility in New York, is poised to play a significant role."
Since April last year, Lotte Biologics has also been inviting global experts such as Professor Nathan Tumey, Ph.D., of the Department of Pharmaceutical Sciences at the State University of New York, Dr. Oren Beske of the American biotechnology company ATUM, Dr. Mark Chiu of Tavotek Biotherapeutics, and Dr. Jonny Finlay of Ottimo Pharma, to share the latest academic information on technology development. Through these efforts, the company is strengthening both its global network and employees' access to cutting-edge knowledge.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Geonhee Jang, Head of Technology Development at Lotte Biologics, commented, "Lotte Biologics is commercializing innovative technologies based on our geopolitical advantages and quality competitiveness. As a global ADC CDMO, we will continue our efforts and hope to contribute new therapeutic options for patients and the medical field."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.